J&J to study rare blood clots linked to AstraZeneca vaccine

2 minutes

ZURICH, April 20- A German scientist studying seriously serious blood clots related to AstraZeneca's COVID 19 vaccine said on Tuesday that Johnson has agreed to work with him on the research after similar rare side effects emerged in recipients of its shot.

Andreas Greinacher, a transfusion medicine expert at Greifswald University, announced the collaboration after European Medicines Agency said it would add a label to J& J's vaccine warning of unusual blood clots with low platelet counts. AstraZeneca's shot has a similar warning: As with Greinacher, the EMA said the clotting risks of getting J& J's shot still outweigh the EMA.

Greinacher, who on Tuesday released a new paper https: www.researchsquare.com article rs 440461 v 1 offering a potential explanation for the complications, wants to study J& J vaccination samples in his lab.

Since mid-March, his team has been analysing specimens from people who had clots after getting the shot from AstraZeneca. Greinacher announced today that we will work together, we agreed during a news conference.

My biggest need, which I have expressed to the company, is that I want to get access to the vaccine, because J& J is not available in Germany. Johnson did not immediately respond to a request for comment.

The EMA said on Tuesday it suspects the vaccine could trigger an specific immune response, but safety committee chairwoman Sabine Straus said it has not identified any unwanted risk factors.

It would be very helpful if we can learn before, whether it might be some kind of genetic disorder or something else in the blood vessels, Straus told reporters.

Greinacher does not believe such a prognostic test is likely based on experience with a serious disorder called heparin-induced thrombocytopenia, which has defied efforts to identify why some people are predisposed to this condition.

We have even genetically sequenced 3,000 of these patients, and we could't find a genetic predisposition, he said.

In the new, not yet peer-reviewed, paper of Greinacher suggests the technology behind AstraZeneca's shot, some of its ingredients and the powerful immune reaction it induces, may contribute to a cascade of events that normally keep the human immune system under control.

Both the AstraZeneca and J& J vaccines use a different cold virus, albeit common ones, to ferry coronavirus proteins to cells to produce an immune response.

Individuals are unique, and only if by coincidence, 9 or 10 weaknesses are coming together, then we have a Greinacher said.

Otherwise, our in-built security systems block it and keep us safe.

  • Comments
Loading comments...